Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q3 2017 · 10-Q
Revenue$534.14M$534.14M+5.0% vs Q3 2016 Net Income$22.10M$22.10M+29.2% vs Q3 2016 EPS Diluted$0.73$0.73+25.9% vs Q3 2016 Gross Profit$299,000,000+7.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$28,475,000−44.8% Free Cash Flowderived$8,162,000−32.8% Margins · derivedGross margin56.0%+1.0 pt vs Q3 2016
Operating margin7.3%+2.8 pt vs Q3 2016
Net margin4.1%+0.8 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 9, 2017 · 40 d after period end